Aspira Women's Health Inc. (AWH)
USD 0.08
(0.0%)
USD 0.08
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 9.15 Million USD | 11.85% |
| 2022 | 8.18 Million USD | 20.14% |
| 2021 | 6.81 Million USD | 46.46% |
| 2020 | 4.65 Million USD | 2.49% |
| 2019 | 4.53 Million USD | 48.64% |
| 2018 | 3.05 Million USD | -2.18% |
| 2017 | 3.12 Million USD | 18.13% |
| 2016 | 2.64 Million USD | 21.36% |
| 2015 | 2.17 Million USD | -13.65% |
| 2014 | 2.52 Million USD | -1.75% |
| 2013 | 2.56 Million USD | 22.54% |
| 2012 | 2.09 Million USD | 8.89% |
| 2011 | 1.92 Million USD | 63.66% |
| 2010 | 1.17 Million USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 124 Thousand USD | 181.82% |
| 2007 | 44 Thousand USD | -99.76% |
| 2006 | 18.21 Million USD | -33.15% |
| 2005 | 27.24 Million USD | -32.19% |
| 2004 | 40.18 Million USD | -31.16% |
| 2003 | 58.37 Million USD | 48.53% |
| 2002 | 39.3 Million USD | 106.31% |
| 2001 | 19.04 Million USD | 113.2% |
| 2000 | 8.93 Million USD | 78.34% |
| 1999 | 5.01 Million USD | 70.81% |
| 1998 | 2.93 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.42 Million USD | 12.54% |
| 2024 Q1 | 2.15 Million USD | 1.08% |
| 2023 Q3 | 2.21 Million USD | -11.0% |
| 2023 Q1 | 2.31 Million USD | 7.57% |
| 2023 FY | 9.15 Million USD | 11.85% |
| 2023 Q2 | 2.49 Million USD | 7.56% |
| 2023 Q4 | 2.13 Million USD | -3.92% |
| 2022 Q3 | 2.07 Million USD | 0.29% |
| 2022 Q2 | 2.06 Million USD | 9.14% |
| 2022 Q1 | 1.89 Million USD | 2.27% |
| 2022 FY | 8.18 Million USD | 20.14% |
| 2022 Q4 | 2.15 Million USD | 3.91% |
| 2021 Q3 | 1.66 Million USD | -7.39% |
| 2021 Q1 | 1.49 Million USD | 3.46% |
| 2021 Q4 | 1.85 Million USD | 11.1% |
| 2021 Q2 | 1.79 Million USD | 20.25% |
| 2021 FY | 6.81 Million USD | 46.46% |
| 2020 Q3 | 1.23 Million USD | 66.09% |
| 2020 Q2 | 746 Thousand USD | -38.85% |
| 2020 FY | 4.65 Million USD | 2.49% |
| 2020 Q1 | 1.22 Million USD | -6.73% |
| 2020 Q4 | 1.44 Million USD | 16.71% |
| 2019 Q3 | 1.28 Million USD | 12.52% |
| 2019 FY | 4.53 Million USD | 48.64% |
| 2019 Q2 | 1.14 Million USD | 42.22% |
| 2019 Q1 | 803 Thousand USD | -12.91% |
| 2019 Q4 | 1.3 Million USD | 1.79% |
| 2018 Q3 | 774 Thousand USD | 9.32% |
| 2018 Q4 | 922 Thousand USD | 19.12% |
| 2018 FY | 3.05 Million USD | -2.18% |
| 2018 Q1 | 649 Thousand USD | -18.67% |
| 2018 Q2 | 708 Thousand USD | 9.09% |
| 2017 Q3 | 699 Thousand USD | -22.16% |
| 2017 Q2 | 898 Thousand USD | 23.69% |
| 2017 Q1 | 726 Thousand USD | -9.81% |
| 2017 FY | 3.12 Million USD | 18.13% |
| 2017 Q4 | 798 Thousand USD | 14.16% |
| 2016 Q3 | 623 Thousand USD | -12.13% |
| 2016 Q1 | 505 Thousand USD | 39.89% |
| 2016 Q2 | 709 Thousand USD | 40.4% |
| 2016 Q4 | 805 Thousand USD | 29.21% |
| 2016 FY | 2.64 Million USD | 21.36% |
| 2015 FY | 2.17 Million USD | -13.65% |
| 2015 Q4 | 361 Thousand USD | 9.39% |
| 2015 Q3 | 330 Thousand USD | -38.32% |
| 2015 Q2 | 535 Thousand USD | -43.74% |
| 2015 Q1 | 951 Thousand USD | -39.39% |
| 2014 Q2 | 324 Thousand USD | 6.23% |
| 2014 Q3 | 323 Thousand USD | -0.31% |
| 2014 FY | 2.52 Million USD | -1.75% |
| 2014 Q4 | 1.56 Million USD | 385.76% |
| 2014 Q1 | 305 Thousand USD | -80.76% |
| 2013 Q1 | 328 Thousand USD | -71.28% |
| 2013 Q3 | 330 Thousand USD | 2.17% |
| 2013 Q2 | 323 Thousand USD | -1.52% |
| 2013 Q4 | 1.58 Million USD | 380.3% |
| 2013 FY | 2.56 Million USD | 22.54% |
| 2012 Q4 | 1.14 Million USD | 257.99% |
| 2012 Q2 | 321 Thousand USD | 2.88% |
| 2012 FY | 2.09 Million USD | 8.89% |
| 2012 Q1 | 312 Thousand USD | -64.06% |
| 2012 Q3 | 319 Thousand USD | -0.62% |
| 2011 Q4 | 868 Thousand USD | 171.25% |
| 2011 Q1 | 431 Thousand USD | 24.93% |
| 2011 Q3 | 320 Thousand USD | 5.26% |
| 2011 Q2 | 304 Thousand USD | -29.47% |
| 2011 FY | 1.92 Million USD | 63.66% |
| 2010 Q4 | 345 Thousand USD | -16.46% |
| 2010 Q3 | 413 Thousand USD | 20.06% |
| 2010 Q2 | 344 Thousand USD | 371.23% |
| 2010 Q1 | 73 Thousand USD | 0.0% |
| 2010 FY | 1.17 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | -100.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q1 | 53 Thousand USD | 130.43% |
| 2008 FY | 124 Thousand USD | 181.82% |
| 2008 Q2 | - USD | -100.0% |
| 2008 Q3 | 71 Thousand USD | 0.0% |
| 2008 Q4 | - USD | -100.0% |
| 2007 Q2 | - USD | -100.0% |
| 2007 Q1 | 21 Thousand USD | -98.27% |
| 2007 FY | 44 Thousand USD | -99.76% |
| 2007 Q4 | 23 Thousand USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q2 | 5.27 Million USD | -25.35% |
| 2006 Q1 | 7.06 Million USD | 7.01% |
| 2006 Q3 | 4.66 Million USD | -11.59% |
| 2006 Q4 | 1.21 Million USD | -73.92% |
| 2006 FY | 18.21 Million USD | -33.15% |
| 2005 FY | 27.24 Million USD | -32.19% |
| 2005 Q1 | 6.64 Million USD | 132.69% |
| 2005 Q3 | 7.05 Million USD | -5.83% |
| 2005 Q4 | 6.6 Million USD | -6.45% |
| 2005 Q2 | 7.49 Million USD | 12.71% |
| 2004 Q2 | 10.75 Million USD | -30.79% |
| 2004 Q1 | 15.53 Million USD | 2.26% |
| 2004 Q3 | 11.03 Million USD | 2.59% |
| 2004 FY | 40.18 Million USD | -31.16% |
| 2004 Q4 | 2.85 Million USD | -74.1% |
| 2003 Q2 | 14.26 Million USD | 11.08% |
| 2003 Q4 | 15.19 Million USD | -5.46% |
| 2003 Q1 | 12.84 Million USD | -5.53% |
| 2003 Q3 | 16.07 Million USD | 12.68% |
| 2003 FY | 58.37 Million USD | 48.53% |
| 2002 Q3 | 10.24 Million USD | 18.35% |
| 2002 Q4 | 13.59 Million USD | 32.72% |
| 2002 FY | 39.3 Million USD | 106.31% |
| 2002 Q1 | 6.81 Million USD | -6.64% |
| 2002 Q2 | 8.65 Million USD | 26.99% |
| 2001 Q1 | 2.68 Million USD | -9.27% |
| 2001 FY | 19.04 Million USD | 113.2% |
| 2001 Q4 | 7.29 Million USD | 35.07% |
| 2001 Q3 | 5.4 Million USD | 47.53% |
| 2001 Q2 | 3.66 Million USD | 36.53% |
| 2000 Q1 | 1.82 Million USD | 0.0% |
| 2000 Q2 | 1.82 Million USD | 0.05% |
| 2000 Q4 | 2.95 Million USD | 26.48% |
| 2000 Q3 | 2.33 Million USD | 28.39% |
| 2000 FY | 8.93 Million USD | 78.34% |
| 1999 FY | 5.01 Million USD | 70.81% |
| 1998 FY | 2.93 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 70.706% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | 31.52% |
| Biodesix, Inc. | 49.08 Million USD | 81.351% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | 6.313% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -261.461% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -261.461% |
| Bionano Genomics, Inc. | 36.11 Million USD | 74.654% |
| CareDx, Inc | 280.32 Million USD | 96.734% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | 95.835% |
| DarioHealth Corp. | 20.35 Million USD | 55.022% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.634% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 96.835% |
| Guardant Health, Inc. | 563.94 Million USD | 98.377% |
| ICON Public Limited Company | 8.12 Billion USD | 99.887% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.75% |
| Illumina, Inc. | 4.5 Billion USD | 99.797% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -194.172% |
| iSpecimen Inc. | 9.92 Million USD | 7.798% |
| Standard BioTools Inc. | 106.34 Million USD | 91.392% |
| MDxHealth SA | 70.19 Million USD | 86.959% |
| 23andMe Holding Co. | 219.63 Million USD | 95.832% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.515% |
| Myriad Genetics, Inc. | 678.4 Million USD | 98.651% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -922.246% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | 98.453% |
| Neogen Corporation | 924.22 Million USD | 99.01% |
| Inotiv, Inc. | 572.42 Million USD | 98.401% |
| Natera, Inc. | 1.08 Billion USD | 99.154% |
| OpGen, Inc. | 3.41 Million USD | -167.792% |
| OPKO Health, Inc. | 863.49 Million USD | 98.94% |
| Psychemedics Corporation | 22.09 Million USD | 58.575% |
| Prenetics Global Limited | 21.74 Million USD | 57.898% |
| Prenetics Global Limited | 21.74 Million USD | 57.898% |
| Precipio, Inc. | 15.19 Million USD | 39.764% |
| Personalis, Inc. | 73.48 Million USD | 87.542% |
| RadNet, Inc. | 1.61 Billion USD | 99.434% |
| Sera Prognostics, Inc. | 306 Thousand USD | -2891.503% |
| Sotera Health Company | 1.04 Billion USD | 99.128% |
| Neuronetics, Inc. | 71.34 Million USD | 87.17% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 80.007% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 80.007% |
| Trinity Biotech plc | 56.83 Million USD | 83.893% |
| T2 Biosystems, Inc. | 7.19 Million USD | -27.263% |
| Twist Bioscience Corporation | 312.97 Million USD | 97.075% |
| Exagen Inc. | 52.54 Million USD | 82.58% |